We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Böbrek Hücreli Karsinomlu Hastaların Demografik Özellikleri ve Tedavi Sonuçları: Tek Merkez Deneyimi.
- Authors
Ulaş, Arife; Bilgin, Burak; Şener Dede, Didem; Köş, F. Tugba; Akıncı, Muhammed Bülent; Şendur, Mehmet Ali Nahit; Yalçın, Bülent
- Abstract
Objectives: The aim of the study was to evaluate demographic characteristics and treatment outcomes of patients with renal cell cancer. Materials and Methods: Data of 100 patients diagnosed with RCC at Atatürk Research and Education Hospital between the years 2005-2014 were analyzed retrospectively. Kaplan-Meier test was performed for survival analysis. Results: Radical nephrectomy was perfomed 64 % of patients, also partial nephrectomy rate was 7%. Histopathologically, clear cell varient's rate was 84%. Most of the patients were stage 4 (55%) and the most common metastatic site was lung (34%). After the development of metastases, first line interferone (IFN) treatment was administered to 62 of patients and 49 of these took tirosine kinase inhibitor after IFN treatment. For all patients, median follow-up time was 24 months and median overall survival (OS) was 3 6 months. We determined that OS was 30 months and progression free survival ( PFS) was 15 months among patients having recieved sunitinib. Fatigue (34.90%) and anemia (27.90%) were the most common grade 3-4 toxicities. In patients who used sunitinib, median PFS in the good, intermediate and poor risk patients according to Memorial Sloan Kettering Cancer Center (MSKCC) criteria respectively were 45.15 and 6 months (p<0.05). In multivariate analysis, we found that age over 65 years (p=0.04), grade 3-4 tumors (p=0.05) and the poor risk according to MSKCC criteria (p=0.04) are associated with decreased overall survival. Conclusion: The majority of our patients were young and had advanced disease at diagnosis. The significantly improvement in survival has been observed between the nephrectomized and metastatic RCC patients who used sunitinib at our clinic.
- Publication
Ankara Medical Journal, 2016, Vol 16, Issue 2, p149
- ISSN
2148-4570
- Publication type
Article
- DOI
10.17098/amj.61112